Poor oral absorption properties in drug candidates can delay critical preclinical and clinical studies, leading to inflated timelines and costs for drug manufacturers. However, utilizing physiologically based pharmacokinetic (PBPK) models to better predict study outcomes can help sponsors understand obstacles to absorption. As a result, they can formulate strategies for improving absorption and reducing associated risks prior to conducting in vivo studies.
In a webinar hosted by Lonza, Deanna Mudie, Ph.D., Senior Principal Engineer at Lonza Small Molecules, and John DiBella, President of Simulations Plus, both discuss the broad potential impact of utilizing PBPK for risk assessment, sharing multiple PBPK case studies. In this article, Deanna and John shared their insights after the webinar on the impact of solid form changes and other solutions that can emerge from PBPK findings.